BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 26457647)

  • 21. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
    Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and treatment of juvenile myelomonocytic leukemia.
    Sakashita K; Matsuda K; Koike K
    Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
    Koike K; Matsuda K
    Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
    Chang TY; Dvorak CC; Loh ML
    Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.
    Kar SA; Jankowska A; Makishima H; Visconte V; Jerez A; Sugimoto Y; Muramatsu H; Traina F; Afable M; Guinta K; Tiu RV; Przychodzen B; Sakaguchi H; Kojima S; Sekeres MA; List AF; McDevitt MA; Maciejewski JP
    Haematologica; 2013 Jan; 98(1):107-13. PubMed ID: 22773603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing.
    Wang WH; Lu MY; Tsai CH; Wang SC; Chou SW; Jou ST
    J Formos Med Assoc; 2021 Apr; 120(4):1148-1152. PubMed ID: 32933826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
    Stieglitz E; Troup CB; Gelston LC; Haliburton J; Chow ED; Yu KB; Akutagawa J; Taylor-Weiner AN; Liu YL; Wang YD; Beckman K; Emanuel PD; Braun BS; Abate A; Gerbing RB; Alonzo TA; Loh ML
    Blood; 2015 Jan; 125(3):516-24. PubMed ID: 25395418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
    Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R
    Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
    Yoshida N; Doisaki S; Kojima S
    Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive congenital juvenile myelomonocytic leukemia associated with somatic KRAS p.G13D mutation and concurrent germline IGF1R duplication.
    Kothari A; Hulbert ML; Cottrell CE; Nguyen TT
    Leuk Lymphoma; 2015 Apr; 56(4):1175-8. PubMed ID: 25110823
    [No Abstract]   [Full Text] [Related]  

  • 33. Myelodysplastic and myeloproliferative disorders of childhood.
    Hasle H
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):598-604. PubMed ID: 27913534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
    Morales CE; Stieglitz E; Kogan SC; Loh ML; Braun BS
    Blood Adv; 2021 Sep; 5(18):3587-3591. PubMed ID: 34464969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.
    Fiñana C; Gómez-Molina N; Alonso-Moreno S; Belver L
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases].
    Yang WY; Liu LP; Liu F; Qi BQ; Chang LX; Zhang L; Chen XJ; Zou Y; Chen YM; Guo Y; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar; 25(3):265-271. PubMed ID: 36946161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy.
    Muraoka M; Okuma C; Kanamitsu K; Ishida H; Kanazawa Y; Washio K; Seki M; Kato M; Takita J; Sato Y; Ogawa S; Tsukahara H; Oda M; Shimada A
    J Hum Genet; 2016 Jun; 61(6):523-6. PubMed ID: 26911351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
    Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
    Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients.
    Coppe A; Nogara L; Pizzuto MS; Cani A; Cesaro S; Masetti R; Locatelli F; Te Kronnie G; Basso G; Bortoluzzi S; Bresolin S
    Hum Mutat; 2018 Apr; 39(4):579-587. PubMed ID: 29316027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.